December 01, 2013

Idenix Pharmaceuticals LLC et al v. Gilead Sciences Inc. et al

View recent docket activity


Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.


Coverage

  1. December 15, 2016

    Idenix Wins $2.5B Verdict In Gilead Hep C Drug Patent Fight

    A federal jury took less than two hours Thursday to award Idenix Pharmaceuticals LLC a $2.54 billion royalty share of Gilead Sciences Inc.'s profits from two blockbuster hepatitis C drugs, after almost nine days of courtroom battling over claims that included willful patent infringement by Gilead.

8 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS